BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics and Radiomics (BALance)
Check the BALance: ARDS Deconvolution by Bronchoalveolar Lavage Multiomics Profiling and Radiomics
Acute respiratory distress syndrome (ARDS) is a major contributor to ICU mortality and is characterised by hypoxaemia and pulmonary oedema. Pathomechanisms include barrier breakdown, immunopathology, haemostatic derailment and dysbiosis; however, the actual sequence of events and how they cumulatively lead to lung failure remains unclear. Although ARDS is frequently triggered by pneumonia, it can also occur as a result of trauma, aspiration or non-pulmonary causes. Importantly, ARDS is highly heterogeneous; growing evidence points to aetiology-specific pathomechanisms - a circumstance that explains why attempts to develop specific drugs or timely diagnostic markers have so far failed.
A comprehensive analysis of key microenvironmental and haemostasis-related parameters of the lung, combined with multidimensional quantitative image features derived from chest CT scans (radiomics), will enable us to i) identify ARDS phenotypes with different biological characteristics and ii) generate new hypotheses regarding aetiology- or subgroup-specific mechanisms, molecular markers and therapeutic options.
Our approach is based on ICU management of our patients guided by bronchoalveolar lavage fluid (BALF). Together with previously sampled cases and new samples collected as part of this study, our cohort will consist of patients with i) COVID-19-associated ARDS, ii) ARDS associated with other viral pneumonia, iii) ARDS associated with bacterial pneumonia, and iv) ARDS of non-pulmonary origin. Bacterial and fungal co-infections and superinfections are recorded in all patients and taken into account in the stratification. Patients with pneumonia without ARDS, as well as ventilated patients without underlying lung disease, serve as controls. To characterise the microbial lung microenvironment, the investigators combine data from routine microbiological diagnostics with microbiome sequencing and metabolomics. In addition, the investigators conduct comprehensive and longitudinal immune and haemostatic profiling by regularly analysing immune cells, cytokines and parameters of immune thrombosis in BALF and blood. Multi-omics integration then identifies phenotypic subgroups by merging all multimodal datasets - including radiomics. Selected samples from identified clusters are then further characterised using single-cell sequencing to uncover specific features/markers and pathomechanisms of the respective ARDS subtypes.
Although it is clear that the pathogenesis of ARDS is multifactorial, comprehensive studies that integrate all relevant parameters are rare. Radiomics is increasingly recognised as a powerful tool for capturing the clinical status of ARDS in detail; however, to date, this imaging data has not been systematically linked to other omics readouts. The investigators aim to bridging this gap by conducting a thorough investigation across various ARDS aetiologies in the present study, incorporating all identifiable key factors.
Our interdisciplinary team comprises basic immunologists, infectious disease and computational biologists, as well as clinicians with expertise in ARDS, infectious diseases, immunothrombosis and radiology.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Oliver Robak, Prof. PD Dr.
- Phone Number: +43 1 40400 44920
- Email: oliver.robak@meduniwien.ac.at
Study Contact Backup
- Name: Riem Gawish, PhD
- Phone Number: +43 1 40400 51480
- Email: riem.gawish@meduniwien.ac.at
Study Locations
-
-
State of Vienna
-
Vienna, State of Vienna, Austria, 1090
- General Hospital of Vienna, Medical University of Vienna
-
Contact:
- Oliver Robak, Ap. Prof. Priv.-Doz. Dr.
- Phone Number: +43 1 40400 44920
- Email: oliver.robak@meduniwien.ac.at
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- male and female
- aged 18 years or over
- signed consent form
- depending on the study group: Confirmed ARDS according to the Berlin criteria (see below, Groups B and D) Confirmed severe CAP requiring mechanical ventilation and intensive care (see below, Groups B and C) Ventilated patients without signs of ARDS (see below, Group E)
Exclusion Criteria:
- under 18 years of age
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
COVID-19 ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Other Names:
|
|
Pneumonia-induced ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Other Names:
|
|
Severe pneumonia but no ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Other Names:
|
|
Non-pulmonary origin ARDS
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Other Names:
|
|
No lung pathology
|
blood will be drawn from patients on day 1 and once a week until discharge/withdrawal/death
mini-BALF using a physiologic saline soluation will be performed on day 1 and once a week until discharge/withdrawal/death
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ARDS phenotypes
Time Frame: 4 years
|
The application of multi-omics cluster analysis to reveal any distinct ARDS phenotypes or subgroup-specific characteristics.
|
4 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lung Microbiome Composition Analysis via 16S rRNA Gene Sequencing of Bronchoalveolar Lavage (BAL) Fluid
Time Frame: 4 years
|
Differences in the microbial community composition (alpha diversity, beta diversity, and taxonomic abundance at phylum/genus level) of the lower respiratory tract microbiome in intensive care patients with ARDS
|
4 years
|
|
Metabolomic Profile of Bronchoalveolar Lavage Fluid and Plasma
Time Frame: 4 years
|
Differences in the metabolomic profile (relative concentrations of annotated metabolites and pathway-level scores) in bronchoalveolar lavage (BAL) fluid and plasma between ARDS subgroups (with vs. without bacterial/fungal co-/superinfection).
Metabolomic measurements will be performed using the METAB02, AMINO01, and LIPID01 or other appropriate packages.
Samples will be analyzed via mass spectrometry to quantify a wide range of analytes, including various amino acids, lipids and their subclasses, and metabolites such as pyruvate, lactate, citrate, and succinate.
|
4 years
|
|
Inflammatory Cytokine Profile in Bronchoalveolar Lavage Fluid and Plasma
Time Frame: 4 years
|
Concentrations of predefined pro- and anti-inflammatory cytokines (e.g., IL-6, IL-8, TNF-α, others according to panel) in BAL fluid and plasma of ARDS patients, and detection of differences between ARDS subgroups (with vs. without bacterial/fungal co-/superinfection) by Multiplex bead-based immunoassay or ELISA panels (e.g., Luminex, electrochemiluminescence).
|
4 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Oliver Robak, Prof. PD Dr., Medical University of Vienna, Department of Medicine 1
- Principal Investigator: Riem Gawish, PhD, Medical University of Vienna, Department of Medicine 1
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Infections
- Infections
- Orthomyxoviridae Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Pneumonia, Viral
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- Lung Injury
- COVID-19
- Influenza, Human
- Pneumonia
- Acute Lung Injury
- Coinfection
- Investigative Techniques
- Therapeutics
- Paracentesis
- Specimen Handling
- Clinical Laboratory Techniques
- Diagnostic Techniques and Procedures
- Diagnosis
- Punctures
- Surgical Procedures, Operative
- Blood Specimen Collection
- Cordocentesis
Other Study ID Numbers
Other Study ID Numbers
- 2405/2025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ARDS (Acute Respiratory Distress Syndrome)
-
NCT07519941Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
NCT07317050Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
NCT07186140Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
NCT07528196Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
NCT07504731RecruitingAcute Respiratory Distress Syndrome (ARDS)
-
NCT07395076RecruitingAcute Respiratory Distress Syndrome (ARDS)
-
NCT07319351CompletedAcute Respiratory Distress Syndrome (ARDS)
-
NCT07545252Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
NCT07516665Not yet recruitingAcute Respiratory Distress Syndrome (ARDS)
-
NCT07414056Recruiting
Clinical Trials on sampling blood
-
NCT04025541RecruitingGlioma | Sarcoma | Cancer | Breast Cancer | Colon Cancer | Lung Cancers
-
NCT02711332Completed
-
NCT04907773Completed
-
NCT06891508Active, not recruiting
-
NCT03788772CompletedSepsis | Acute Circulatory Failure
-
NCT03857997CompletedPatients With Intellectual Disabilities Without an Obvious Clinical Diagnosis | Patients With Normal Array CGH and Previous Negative Genetic Investigations (WES-solo or WES-trio)
-
NCT04697407Completed
-
NCT03388034CompletedBordetella Pertussis, Whooping Cough
-
NCT03606252CompletedPneumonia, Pneumocystis